Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

Item

http://www.wikidata.org/entity/Q36339698

Q36339698

about

Cardiac toxicity of trastuzumab in elderly patients with breast cancer How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Are we ready to predict late effects? A systematic review of clinically useful prediction models.Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter Twenty years of anti-HER2 therapy-associated cardiotoxicity Cardiac risk in the treatment of breast cancer: assessment and management.Long term side effects of adjuvant chemotherapy in patients with early breast cancer Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Cardiac complications of chemotherapy: role of imaging.Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer.Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer.HER2 signaling pathway and trastuzumab cardiotoxicity.Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience.Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.Cardiovascular toxicities from systemic breast cancer therapy.Cardiotoxicity and oncological treatments.Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study.Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)Roadmap for biomarkers of cancer therapy cardiotoxicity.Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer Adjuvant trastuzumab: does time really matter?Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.

P2860

Q26741182-5F4273B1-EECA-43F3-92E2-7DAAD5288E92 Q26824542-9B328307-A4FC-494F-880A-FDD213362C93 Q27025860-E1C2FADE-C357-4300-821F-5077E747D07D Q27311616-3F84BC4D-2ECF-4BB5-97F5-46A1F73E5A29 Q28068290-385422C6-2E86-4A4C-9575-D206977121A5 Q28075864-B727629E-94B2-4085-B9A8-2CE6E1F8F64C Q28079391-41B82B3E-0A53-40D3-B579-9126F73BE4C8 Q28081385-BE884E9C-E767-40EF-B48C-9FFC35D61AC0 Q28083233-5B79D9D4-6477-4967-A704-665D75B1D2A9 Q28260063-F7A29F12-E1FA-4D4F-8910-16BB58198D06 Q28291395-2D9AC11C-12A6-4D36-B0A0-122173B1864A Q30371966-677292CF-8A21-4463-A380-1A5F2970774F Q30415201-80301048-BF36-41FA-8F9F-ACD69A908709 Q31004660-E96183A7-1F3B-43E5-B697-AE7B775E3684 Q33433275-BB238747-51C1-4B78-9F91-4C7F1F66B056 Q33824842-64CF910F-36A4-41AD-B02F-BD5B2AA49629 Q33840140-3D557609-6AE2-4ACE-B992-C835B24C44DC Q33862786-395D6725-545C-4EAA-AF62-C9EF8EC62410 Q33886306-8AA4F85F-5250-469A-9A45-70712B7DBBFF Q34049037-68AD61C5-20AE-451A-AEF7-83FB5871CAE4 Q34104204-B7D05DD8-8065-4484-8AD0-4364CC746DAE Q34328064-344D4527-3C5B-4A92-A1AC-07A70DE31B31 Q34403544-E7BEC74E-6B66-4B80-AED2-9AEC17FC145B Q34441749-DEB531E7-4E1F-4352-A6EF-6D92CB08D5EC Q34484185-006705E0-7EA7-4718-97B5-CD91E05F2E7C Q34630349-D1873116-9A8D-4626-9341-34A8686AEDC9 Q34660647-7DDAC4D6-D1D7-435C-863B-E3D594FCE437 Q34779675-2B835E95-47E1-4E81-AAF2-6269BA57CBB1 Q35667318-A4386D79-493A-44E0-8A31-B377D5AB4552 Q35909719-711406D7-8C0E-4820-998F-1622B2C5F82D Q35947005-83E04D80-F516-49B2-BC70-F268EC2A9215 Q35963154-A00325EB-DFC1-403E-8725-E195D78EC5E9 Q36098713-76CBD359-0840-49B3-BA3A-691BF2315CD1 Q36116313-F6E3D67E-32BF-4469-A473-0F446DAF71B1 Q36432099-E31A81D0-453C-439E-A31F-64904055E6DA Q36626934-492B03B5-CCE2-4DAA-96A9-771AA734CB7C Q36637796-015D5A60-06AC-4B16-A106-AE1FF7D26E6B Q36788268-9629F71E-01DA-4B32-B06F-E4FE0A85FFB1 Q36871644-B4EFAB18-30B1-4273-AF7C-E35C7F9D2D20 Q36884357-3AC3AD01-BC69-44C5-86C5-A8852B21A73E

P2860

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

Item

http://www.wikidata.org/entity/Q36339698

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Seven-year follow-up assessmen ...... th node-positive, human epider

@ast

Seven-year follow-up assessmen ...... th node-positive, human epider

@en

type

Item

label

Seven-year follow-up assessmen ...... th node-positive, human epider

@ast

Seven-year follow-up assessmen ...... th node-positive, human epider

@en

prefLabel

Seven-year follow-up assessmen ...... th node-positive, human epider

@ast

Seven-year follow-up assessmen ...... th node-positive, human epider

@en

P1476

Seven-year follow-up assessmen ...... eptor 2-positive breast cancer

@en

P2093

Adam Brufsky

http://www.w3.org/2001/XMLSchema#string

Catherine A Azar

http://www.w3.org/2001/XMLSchema#string

Charles E Geyer

http://www.w3.org/2001/XMLSchema#string

David D Biggs

http://www.w3.org/2001/XMLSchema#string

Edward H Romond

http://www.w3.org/2001/XMLSchema#string

Eleftherios P Mamounas

http://www.w3.org/2001/XMLSchema#string

Elizabeth Tan-Chiu

http://www.w3.org/2001/XMLSchema#string

Howard M Gross

http://www.w3.org/2001/XMLSchema#string

James N Atkins

http://www.w3.org/2001/XMLSchema#string

John L Zapas

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data.

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Evaluating the yield of medical tests.

Adjuvant trastuzumab in HER2-positive breast cancer.

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

P304

3792-3799

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.40.0010

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sandra M. Swain

Greg Yothers

Jong-Hyeon Jeong

P577

2012-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22987084

http://www.w3.org/2001/XMLSchema#string

P932

3478574

http://www.w3.org/2001/XMLSchema#string

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

about

P2860

P2860

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932